News

67 Articles found

News Press Releases Locus Insights

January 4, 2019

Microbiome Times: Locus Biosciences Enters Collaboration and License Agreement with J&J to Develop CRISPR-Cas3 Bacteriophage Therapeutics

Learn More
January 4, 2019

Pharmaceutical Technology: Janssen signs a $818m CRISPR products deal with Locus Biosciences

Learn More
January 3, 2019

Fierce Biotech: J&J takes stake in Locus’ CRISPR-based ‘Pac-Man’ antimicrobials

Learn More
January 3, 2019

Seeking Alpha: J&J teams up with Locus Biosciences to develop CRISPR-based therapies for infections

Learn More
January 3, 2019

BioSpace: Locus and Janssen Ink Potential $818 Million Deal to Develop CRISPR-Based Antibacterials

Learn More
January 3, 2019

WRAL TechWire: Locus Biosciences lands $20M upfront, could earn nearly $800M in licensing deal

Learn More
January 3, 2019

Bloomberg: J&J Bets $20 Million on DNA Tool to Battle Infectious Bacteria

Learn More
January 3, 2019

TechCrunch: Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

Learn More
January 2, 2019

Nature highlighted Locus’ CRISPR-enhanced phage therapy for antibiotic-resistant bacterial infections in its “What to expect in 2018” article.

Learn More
November 29, 2018

We’re proud to be selected Best Initial Venture Funding and to be recognized alongside fellow North Carolina companies

Learn More